Bipolar II Disorder

Neurology
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Quetiapine/SeroquelPhase 41 trial
Active Trials
NCT00186043Completed55Est. Aug 2011
Alliance Pharmaceuticals
1 program
1
Interpersonal and Social Rhythm TherapyPhase 2/31 trial
Active Trials
NCT00411463Completed25Est. Sep 2010
GH Research
GH ResearchDUBLIN 2, Ireland
1 program
1
GH001Phase 21 trial
Active Trials
NCT05839509TerminatedEst. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaQuetiapine/Seroquel
Alliance PharmaceuticalsInterpersonal and Social Rhythm Therapy
GH ResearchGH001

Clinical Trials (3)

Total enrollment: 80 patients across 3 trials

NCT00186043AstraZenecaQuetiapine/Seroquel

Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II

Start: Aug 2008Est. completion: Aug 201155 patients
Phase 4Completed
NCT00411463Alliance PharmaceuticalsInterpersonal and Social Rhythm Therapy

Psychotherapy for Bipolar II Depression, Pilot Study, Phase II

Start: Dec 2006Est. completion: Sep 201025 patients
Phase 2/3Completed

Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

Start: Apr 2023Est. completion: Dec 2024
Phase 2Terminated

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space